5-HT(1A) receptor activation contributes to ziprasidone-induced dopamine release in the rat prefrontal cortex

BACKGROUND

Ziprasidone (Zeldox) is a novel antipsychotic with a unique combination of antagonist activities at monoaminergic receptors and transporters and potent agonist activity at serotonin 5-HT(1A) receptors. 5-HT(1A) receptor agonism may be an important feature in ziprasidone's clinical actions because 5-HT(1A) agonists increase cortical dopamine release, which may underlie efficacy against negative symptoms and reduce dopamine D(2) antagonist-induced extrapyramidal side effects. This study investigated the in vivo 5-HT(1A) agonist activity of ziprasidone by measuring the contribution of 5-HT(1A) receptor activation to the ziprasidone-induced cortical dopamine release in rats.

METHODS

Effects on dopamine release were measured by microdialysis in prefrontal cortex and striatum. The role of 5-HT(1A) receptor activation was estimated by assessing the sensitivity of the response to pretreatment with the 5-HT(1A) antagonist, WAY-100635. For comparison, the D(2)/5-HT(2A) antagonists clozapine and olanzapine, the D(2) antagonist haloperidol, the 5-HT(2A) antagonist MDL 100,907 and the 5-HT(1A) agonist 8-OHDPAT were included.

RESULTS

Low doses (<3.2 mg/kg) of ziprasidone, clozapine, and olanzapine increased dopamine release to approximately the same extent in prefrontal cortex as in striatum, but higher doses (> or =3.2 mg/kg) resulted in an increasingly preferential effect on cortical dopamine release. The 5-HT(1A) agonist 8-OHDPAT produced a robust increase in cortical dopamine (DA) release without affecting striatal DA release. In contrast, the D(2) antagonist haloperidol selectively increased striatal DA release, whereas the 5-HT(2A) antagonist MDL 100,907 had no effect on cortical or striatal DA release. Prior administration of WAY-100635 completely blocked the cortical DA increase produced by 8-OHDPAT and significantly attenuated the ziprasidone- and clozapine-induced cortical DA increase. WAY-100635 pretreatment had no effect on the olanzapine-induced DA increase.

CONCLUSIONS

The preferential increase in DA release in rat prefrontal cortex produced by ziprasidone is mediated by 5-HT(1A) receptor activation. This result extends and confirms other in vitro and in vivo data suggesting that ziprasidone, like clozapine, acts as a 5-HT(1A) receptor agonist in vivo, which may contribute to its activity as an antipsychotic with efficacy against negative symptoms and a low extrapyramidal side effect liability.

Comparison of the novel antipsychotic ziprasidone with clozapine and olanzapine: inhibition of dorsal raphe cell firing and the role of 5-HT1A receptor activation

Ziprasidone is a novel antipsychotic agent which binds with high affinity to 5-HT1A receptors (Ki = 3.4 nM), in addition to 5-HT1D, 5-HT2, and D2 sites. While it is an antagonist at these latter receptors, ziprasidone behaves as a 5-HT1A agonist in vitro in adenylate cyclase measurements. The goal of the present study was to examine the 5-HT1A properties of ziprasidone in vivo using as a marker of central 5-HT1A activity the inhibition of firing of serotonin-containing neurons in the dorsal raphe nucleus. In anesthetized rats, ziprasidone dose-dependently slowed raphe unit activity (ED50 = 300 micrograms/kg i.v.) as did the atypical antipsychotics clozapine (ED50 = 250 micrograms/kg i.v.) and olanzapine (ED50 = 1000 micrograms/kg i.v.). Pretreatment with the 5-HT1A antagonist WAY-100,635 (10 micrograms/kg i.v.) prevented the ziprasidone-induced inhibition; the same dose of WAY-100,635 had little effect on the inhibition produced by clozapine and olanzapine. Because all three agents also bind to alpha 1 receptors, antagonists of which inhibit serotonin neuronal firing, this aspect of their pharmacology was assessed with desipramine (DMI), a NE re-uptake blocker previously shown to reverse the effects of alpha 1 antagonists on raphe unit activity. DMI (5 mg/kg i.v.) failed to reverse the inhibitory effect of ziprasidone but produced nearly complete reversal of that of clozapine and olanzapine. These profiles suggest a mechanism of action for each agent, 5-HT1A agonism for ziprasidone and alpha 1 antagonism for clozapine and olanzapine. The 5-HT1A agonist activity reported here clearly distinguishes ziprasidone from currently available antipsychotic agents and suggests that this property may play a significant role in its pharmacologic actions.

Combined administration of a 5-hydroxytryptamine (5-HT)1D antagonist and a 5-HT reuptake inhibitor synergistically increases 5-HT release in guinea pig hypothalamus in vivo

In vivo microdialysis in guinea pig hypothalamus was used to study the effect of serotonin [5-hydroxytryptamine (5-HT)] subtype 1D autoreceptor blockade on the increase in extracellular 5-HT levels produced by a selective 5-HT reuptake inhibitor (SSRI). Administration of the selective 5-HT1D antagonist GR127935 at 0.3 mg/kg had no effect, but 5 mg/kg significantly increased extracellular levels of 5-HT and 5-hydroxyindoleacetic acid to 135% of basal values. Moreover, at these doses GR127935 significantly attenuated the decrease in extracellular 5-HT levels following local perfusion with the selective 5-HT1D agonist CP-135,807. The SSRI sertraline at 2 mg/kg increased 5-HT levels to 130% of basal levels. The combination of this low dose of sertraline with either dose of GR127935 resulted in a pronounced, long-lasting increases in 5-HT levels to 230% of basal values. These results indicate that the effects of an SSRI on terminal 5-HT are significantly enhanced by coadministration of a 5-HT1D antagonist and confirm that in addition to somatodendritic 5-HT1A autoreceptors, terminal 5-HT1D autoreceptors mitigate the effect of SSRIs on terminal 5-HT. As such, antagonists of the 5-HT1D autoreceptor could be useful as rapidly acting antidepressants and may shorten the onset of antidepressant action when combined with SSRIs.

Tryptophan pretreatment augmentation of p-chloroamphetamine-induced serotonin and dopamine release and reduction of long-term neurotoxicity

The impact of tryptophan (TRP) pretreatment on the neurochemical effects of p-chloroamphetamine (PCA) was investigated. The neurotoxic effects of PCA on serotonin (5-HT) neurons, the acute effects of PCA on extracellular 5-HT and dopamine (DA), and the displacement by PCA of whole blood 5-HT were examined. TRP pretreatment (400 mg/kg of the methyl ester) significantly reduced the long-term (1 week) decrease in tissue 5-HT resulting from PCA (2 mg/kg, i.p., of the hydrochloride salt) in the prefrontal cortex and striatum, but not in the dorsal hippocampus. Microdialysis studies in awake animals showed that this pretreatment regimen resulted in augmented PCA-induced increases in extracellular 5-HT (4-fold) and DA (2-fold). TRP pretreatment also resulted in increased displacement of 5-HT from whole blood. The implications of these results toward possible mechanisms of action of PCA-induced neurotoxicity are discussed.

Apparent regional differences in 5-HT1A binding may reflect [3H]8-OH-DPAT labeling of serotonin uptake sites

The binding of [3H]8-OH-DPAT and [3H]paroxetine to 5-HT1A and 5-HT uptake sites (respectively) was examined in membranes prepared from bovine dorsal raphe and hippocampus. KD and Bmax values for [3H]8-OH-DPAT binding were indistinguishable in dorsal raphe nucleus and hippocampus. Competition studies with MDL 73,005EF, a selective 5-HT1A ligand, revealed a high and a low affinity site in the dorsal raphe, but only the high affinity component in hippocampal membranes. The low affinity component in the dorsal raphe was reduced in the presence of fluoxetine; saturation isotherms with [3H]paroxetine indicated a 5-fold greater concentration of 5-HT uptake sites in this region. The results are discussed in the context of earlier reports of regional differences in the pharmacology of 5-HT1A receptors and the selectivity of [3H]8-OH-DPAT binding.

Inhibition of dorsal raphe cell firing by MDL 73005EF, a novel 5-HT1A receptor ligand

The effect of a novel ligand for the 5-HT1A receptor subtype, MDL 73005EF, on the firing rate of serotonergic dorsal raphe neurons was assessed in rat midbrain slices maintained in vitro. Superfusion with MDL 73005EF inhibited neuronal firing in a concentration-dependent manner. Based upon IC50 values, MDL 73005EF was equipotent with buspirone (129 +/- 34 vs. 97 +/- 8 nM, respectively) but significantly less potent than 8-OH-DPAT (8-hydroxy-2(di-n-propylamino)tetralin; 7 +/- 2 nM). Pretreatment with (-)-propranolol (1 microM), a mixed 5-HT1A/B receptor antagonist, blocked by 50% the inhibition of unit activity elicited by MDL 73005EF. Taken together, these data suggest that MDL 73005EF is an agonist at the somatodendritic autoreceptor on dorsal raphe neurons, a 5-HT1A receptor which regulates in part the pacemaker activity of these cells. The results are discussed in the context of receptor reserve, recently proposed to explain apparent discrepancies in the actions of agonists at pre- and postsynaptic 5-HT1A sites.

In vitro microdialysis: a novel technique for stimulated neurotransmitter release measurements

A novel microdialysis technique suitable for parallel measurements of neurotransmitter release and single unit recordings from brain slices is presented. The effects of 3,4-methylenedioxymethamphetamine (MDMA) on slices of dorsal raphe nucleus and frontal cortex in a perfusion chamber for electrophysiological measures were studied. MDMA caused measurable release of serotonin which, in the case of the dorsal raphe, was of similar duration as the period of reduced cell firing induced by MDMA. Tryptophan potentiated the action of MDMA. Possible additional applications of this technique are discussed.

Electrophysiology of the central serotonin system: receptor subtypes and transducer mechanisms

It is becoming evident that the diverse electrophysiological actions of 5-HT in the central nervous system can be best formulated in terms of receptor subtypes and their respective effector mechanisms. Based on the findings described in this review, the following pattern of central 5-HT electrophysiology is emerging: 1) inhibitory effects are mediated by 5-HT1 receptors linked to the opening of K channels via pertussis-toxin sensitive G proteins: 2) facilitatory effects are mediated by 5-HT2 receptors and involve the closing of K channels, an effect which appears to be negatively modulated by activation of the PI second messenger system: 3) fast excitations are mediated by 5-HT3 receptors, most likely involving a direct interaction with an ion channel rather than through coupling with a G protein or a second messenger. Further studies will be required in a wider range of brain areas to establish the generality of these conclusions.

3,4-Methylenedioxymethamphetamine-induced release of serotonin and inhibition of dorsal raphe cell firing: potentiation by L-tryptophan

The effects of the serotonin (5-HT) precursor L-tryptophan on MDMA (3,4-methylenedioxymethamphetamine)-induced inhibition of dorsal raphe neuronal firing were characterized using extracellular single-unit recording and microdialysis techniques in the in vitro midbrain slice preparation. Pretreatment with L-tryptophan (100 microM) lowered the doses of MDMA required to inhibit unit activity. Based upon IC50 values, L-tryptophan increased the potency of MDMA by approximately 3-fold. In a parallel series of experiments, microdialysis probes resting on the brain slice surface provided a means to estimate 5-HT release from the dorsal raphe nucleus. Pretreatment with L-tryptophan increased MDMA-induced 5-HT release in a manner consistent with the suppression of dorsal raphe cell firing: compared to untreated preparations, peak 5-HT release, total release and the duration of release were all increased. Taken together, these data suggest that the enhancement by L-tryptophan of MDMA-induced 5-HT release and inhibition of dorsal raphe neuronal firing is due to an increase in the amount of 5-HT available for release. The question is raised as to what effect L-tryptophan may have on the psychotropic and neurotoxic actions of MDMA.

MDMA (3,4-methylenedioxymethamphetamine) inhibits the firing of dorsal raphe neurons in brain slices via release of serotonin

The effects of MDMA (3,4-methylenedioxymethamphetamine) on the activity of serotonin (5-HT)-containing dorsal raphe neurons were characterized using extracellular single-unit recording and microdialysis techniques in the in vitro midbrain slice preparation. Addition of (+)-MDMA, (-)-MDMA or p-chloroamphetamine (PCA) to the superfusate (final concentration 3-100 microM) produced a concentration-dependent inhibition of 5-HT cell firing which was reversible and reproducible. Based upon IC50 values, (+)-MDMA was 2- to 3-fold more potent than (-)-MDMA. Pretreatment with the selective 5-HT uptake inhibitor fluoxetine, at a concentration which had no effect on baseline firing (20 microM), blocked the inhibitory effect of (+)-MDMA and PCA on dorsal raphe neurons. The selective norepinephrine uptake inhibitor desipramine (20 microM) was ineffective. In a parallel series of experiments, microdialysis probes resting on the brain slice surface provided a means to estimate 5-HT release from the dorsal raphe nucleus. (+)-MDMA (100 microM) caused the release of measureable quantities of 5-HT with a time course which corresponded to the change in dorsal raphe cell firing rate. Taken together, these data suggest that MDMA acts indirectly to inhibit dorsal raphe neurons through release of endogenous 5-HT.

Responses of hippocampal pyramidal cells to putative serotonin 5-HT1A and 5-HT1B agonists: a comparative study with dorsal raphe neurons

In low cerveau isolé transected rats, the effects of microiontophoretic application of putative serotonin 5-HT1A and 5-HT1B agonists on the spontaneous firing rate of CA1 pyramidal cells were compared to those of 5-HT. In contrast to the large current-dependent suppression of unit activity observed with 5-HT, the 5-HT1A compounds, ipsapirone, 8-OH-DPAT (8-hydroxy-2-(di-n-propylamino)-tetralin) and LY 165163 (p-aminophenylethyl-m-trifluoromethylphenylpiperazine) and the 5-HT1B compounds, mCPP (m-chlorophenylpiperazine) and TFMPP (trifluoromethylphenylpiperazine), produced only weak inhibition of spontaneous firing. Conversely, using identical ejection parameters, ipsapirone and LY 165163 (previously reported) and 8-OH-DPAT were as effective as 5-HT in inhibiting markedly the baseline activity of serotonergic dorsal raphe neurons; mCPP and TFMPP (previously reported) were only weakly active. In view of the minor suppressant effects of the 5-HT1A agonists on the firing of pyramidal cells, a modulatory role for these compounds was sought. Excitation of pyrimadal cells, induced by microiontophoretic application of glutamate, was attenuated by ipsapirone and 8-OH-DPAT; however, when directly compared in the same cells, ipsapirone was no more effective than the 5-HT1B agonist, mCPP. In summary, the inability of CA1 pyramidal cells to distinguish the actions of 5-HT1A and 5-HT1B ligands is in sharp contrast to the striking differences observed for these compounds with dorsal raphe neurons. Consistent with these findings is the idea that 5-HT1A compounds are full agonists on dorsal raphe neurons but only partial agonists on pyramidal cells.

Electrophysiological responses of serotoninergic dorsal raphe neurons to 5-HT1A and 5-HT1B agonists

A direct comparison was made of the effects of serotonin 5-HT1A and 5-HT1B selective compounds on the spontaneous firing rate of dorsal raphe serotoninergic neurons in chloral-hydrate-anesthetized rats. Following intravenous administration, the 5-HT1A selective compounds ipsapirone (TVX Q 7821) and LY 165163 potently inhibited single-unit activity in a dose-dependent manner whereas the 5-HT1B selective compounds, m-chlorophenylpiperazine (mCPP) and trifluoromethylphenylpiperazine (TFMPP), displayed only weak or irregular actions. Low microiontophoretic currents of ipsapirone and LY 165163 were also effective in suppressing spontaneous firing; dose-response relationships for the 5-HT1A compounds were indistinguishable from that of 5-HT itself. In contrast, dorsal raphe neurons were only weakly responsive to microiontophoretic application of mCPP and TFMPP; dose-response relationships for the 5-HT1B compounds were significantly displaced from that of 5-HT. In intracellular studies, ipsapirone and LY 165163, when added to the media bathing brain slices, mimicked the actions of 5-HT in hyperpolarizing dorsal raphe cell membranes and decreasing input resistance; however, the maximal effects of the 5-HT1A compounds on these membrane properties exceeded those of 5-HT. In summary, dorsal raphe 5-HT neurons appear highly responsive to 5-HT1A, but not to 5-HT1B compounds; these findings are discussed with regard to the 5-HT receptor subtypes as candidates for the somatodendritic autoreceptor of dorsal raphe neurons.

(-)-Propranolol blocks the inhibition of serotonergic dorsal raphe cell firing by 5-HT1A selective agonists

The ability of the beta-adrenoceptor antagonist propranolol to block the effects of serotonin (5-HT) and 5-HT1A-selective agonists on the spontaneous firing of serotonergic dorsal raphe neurons was assessed. During microiontophoretic application, (-)- but not (+)-propranolol rapidly and reversibly blocked the suppressant effects of the 5-HT1A-selective agonists ipsapirone (TVX Q 7821) and 8-hydroxy-2-(di-n-propylamino)tetralin (8-OH-DPAT). However, (-)-propranolol was a relatively weak antagonist of 5-HT itself, suggesting that the endogenous neurotransmitter may have actions on dorsal raphe neurons in addition to those mediated by 5-HT1A receptors.

Pharmacologic excitability of rat motor nerve endings: the effect of adrenalectomy on neostigmine-induced fasciculations

Neostigmine-induced muscle fasciculations, quantitated as fasciculatory muscle action potentials, served as an indirect in vivo indicator of motor nerve ending (MNE) excitability. By this method, MNE excitability was depressed in adrenalectomized rats compared to matched intact controls. Daily or continuous administration of the mineralocorticoids aldosterone or desoxycorticosterone acetate restored MNE excitability toward normal; corticosterone, the endogenous corticosteroid having both mineralo- and glucocorticoid activity, was variably effective. There was a strong negative correlation (r = -0.95) between log plasma [K+]and the fasciculatory response to neostigmine. Dietary restriction of K in adrenalectomized rats lowered plasma [K+]to near normal and significantly increased MNE excitability. This effect of adrenalectomy on MNE excitability was further demonstrated by recording directly the neostigmine-induced repetitive neural discharges responsible for the muscle fasciculations. In adrenalectomized animals, neostigmine-induced neural discharges were reduced in intensity; restoration of neostigmine responsiveness was attained by lowering plasma [K+]through dietary restriction. Stimulus strength-duration relationships for both ventral and dorsal roots disclosed deficits in axonal excitability after adrenalectomy. These returned toward normal when plasma [K+]was lowered by K withdrawal from the diet. From these studies, it is concluded that 1) in adrenalectomized rats, peripheral nerve excitability, including the unmyelinated endings of motor nerve, is depressed; 2) mineralocorticoids play a significant role in restoring MNE excitability in these animals; 3) mineralocorticoid-induced changes in MNE excitability relate to the lowering of an elevated plasma [K+].

Measurement of fasciculations as motor nerve ending discharges in the rat: a dose related effect of neostigmine

The muscle fasciculations caused by neostigmine and similar agents are the result of a primary drug action on motor nerve endings. Asynchronous, repetitive firing of action potentials are evoked at motor nerve endings which are then transmitted to muscle. A dose-response relationship between neostigmine dose and the rate of/or total neural activity has been established in the rat. This fasciculatory response to neostigmine can serve as an index of motor nerve ending excitability and may be useful in assessing the effects of certain pathological states or drug actions at the neuromuscular junction.

Effect of coadministration of procainamide and isoniazid on each other's acetylation pathway

The effect of isoniazid (INH) and procainamide (PA) on each other's acetylation pathway was studied in 7 normal subjects (3 rapid acetylators, 3 slow acetylators, 1 of indeterminate phenotype). Oral PA (6 mg/kg) was administered every 4 h for a total of seven doses. Following the final dose subjects received a single 300-mg oral dose of INH. Analysis of the parent drugs and their acetylated metabolites in plasma and urine revealed no effect on the acetylation of either drug. In 2 subjects (1 rapid, 1 slow acetylator) increasing doses of PA were given and the effect on INH (300 mg) acetylation measured. High mean circulating levels of PA (7.1 microgram/ml) appeared to inhibit acetylation of INH in the rapid acetylator whereas a mean PA plasma level of 8.6 microgram/ml had no effect on INH acetylation in the slow acetylator. However, the results from this study suggest that alterations of INH acetylation by PA are unlikely to be of clinical significance.

The effect of isoniazid and other drugs on the acetylation of procainamide in the intact rat

The effects of isoniazid (INH), hydralazine, salicylazosulfapyridine, and sulfapyridine on the quantitative disposition of procainamide (PA) in the intact rat were examined. A dose-dependent inhibition of PA acetylation was observed after coadministration of PA with INH via nasogastric intubation. The 24-hr urinary excretion of N-acetylprocainamide was noted to decline in the presence of INH whereas that of the unchanged drug exhibited a coincident rise. A reduction in the systemic clearance of PA and a prolongation in its half-life of elimination was also observed. INH increased PA hepatic levels and decreased N-acetylprocainamide hepatic content. In contrast hydralazine affects not only PA acetylation but also its absorption rate and transformation by other metabolic pathways. Salicylazosulfapyridine did not affect PA acetylation whereas high doses of sulfaphridine did.

The effect of hydralazine and other drugs on the kinetics of procainamide acetylation by rat liver and kidney N-acetyltransferase

The objectives of this study were to investigate 1) the tissue distribution of procainamide acetylase activity in the rat and 2) the kinetics of procainamide acetylation by rat liver and kidney N-acetyltransferase and 3) to determine the effect of drugs thought to be similarly acetylated on procainamide acetylation. The cytosol fraction (100,000 X g) of tissue homogenates served as the source of N-acetyltransferase. Of the tissues studied the liver possessed the greatest acetylase activity followed by the kidney, lung, intestine and spleen. The apparent procainamide Michalis constant (Km) for liver and kidney was 2.03 X 10(-4) and 2.09 X 10(-4) M in the presence of 4.2 X 10(-4) M acetyl CoA. The liver Km for procainamide with "infinite" acetylCoA concentration was 4.36 X 10(-3) M. The liver Km for acetyl CoA in the presence of "infinite" PA concentration was 2.44 X 10(-3) M. Hydralazine, para-aminobenzoic acid, isoniazid, and sulfapyridine competitively inhibited procainamide acetylation by liver and kidney N-acetyltransferase.